"Designer Drugs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs designed and synthesized, often for illegal street use, by modification of existing drug structures (e.g., amphetamines). Of special interest are MPTP (a reverse ester of meperidine), MDA (3,4-methylenedioxyamphetamine), and MDMA (3,4-methylenedioxymethamphetamine). Many drugs act on the aminergic system, the physiologically active biogenic amines.
| Descriptor ID |
D015198
|
| MeSH Number(s) |
D26.200
|
| Concept/Terms |
Designer Drugs- Designer Drugs
- Drugs, Designer
- Customized Drugs
- Drugs, Customized
|
Below are MeSH descriptors whose meaning is more general than "Designer Drugs".
Below are MeSH descriptors whose meaning is more specific than "Designer Drugs".
This graph shows the total number of publications written about "Designer Drugs" by people in this website by year, and whether "Designer Drugs" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 5 | 1 | 6 |
| 2013 | 4 | 1 | 5 |
| 2014 | 7 | 0 | 7 |
| 2015 | 6 | 1 | 7 |
| 2016 | 5 | 1 | 6 |
| 2017 | 6 | 0 | 6 |
| 2018 | 3 | 0 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 3 | 1 | 4 |
| 2021 | 3 | 0 | 3 |
| 2022 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
| 2024 | 2 | 0 | 2 |
Below are the most recent publications written about "Designer Drugs" by people in Profiles.
-
Designer Receptor Exclusively Activated by Designer Drug (DREADD)-Mediated Activation of the Periaqueductal Gray Restores Nociceptive Descending Inhibition After Traumatic Brain Injury in Rats. J Neurotrauma. 2024 07; 41(13-14):e1761-e1779.
-
The surge of bromazolam-related fatalities replacing other novel designer benzodiazepines-related fatalities in San Francisco. Addiction. 2024 Aug; 119(8):1487-1490.
-
Designer drugs. Lab Med. 2023 11 02; 54(6):553-554.
-
A head-to-head comparison of two DREADD agonists for suppressing operant behavior in rats via VTA dopamine neuron inhibition. Psychopharmacology (Berl). 2023 Oct; 240(10):2101-2110.
-
Validation of DREADD agonists and administration route in a murine model of sleep enhancement. J Neurosci Methods. 2022 Oct 01; 380:109679.
-
Activation of the Locus Coeruleus Mediated by Designer Receptor Exclusively Activated by Designer Drug Restores Descending Nociceptive Inhibition after Traumatic Brain Injury in Rats. J Neurotrauma. 2022 07; 39(13-14):964-978.
-
Effects of α-pyrrolidino-phenone cathinone stimulants on locomotor behavior in female rats. Drug Alcohol Depend. 2021 10 01; 227:108910.
-
Psychedelic-inspired drug discovery using an engineered biosensor. Cell. 2021 05 13; 184(10):2779-2792.e18.
-
Dreadds: Use and application in behavioral neuroscience. Behav Neurosci. 2021 Apr; 135(2):89-107.
-
MDPV self-administration in female rats: influence of reinforcement history. Psychopharmacology (Berl). 2021 Mar; 238(3):735-744.